A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma

Disease Characteristics:

- Patients with a documented histologic or cytologic diagnosis of a pancreatic
malignancy

- Patients with recurrent, advanced and/or metastatic disease, who have either failed
standard therapy or are not eligible for any alternate therapies of higher
therapeutic priority.

- Patients with at least one identified (confirmed) and measureable tumor site.

Prior/Concurrent Therapy:

- Surgery: Patients are excluded if they have had major surgery either during or within
four weeks prior to study entry.

- Chemotherapy: Patients must have failed standard therapy or are not eligible for any
alternate therapies of higher therapeutic priority.

- Biologic Therapy: Patients who have received a chimeric, CDR-grafted (humanized), or
human IgG will be eligible provided pre-study evaluations demonstrate no significant
reactivity with hMN14 IgG (i.e., HAHA)

- Radiotherapy: No prior radiotherapy within four weeks of study entry. No prior
external beam irradiation to a field that includes more than 30% of the red marrow.
No prior radiation to maximal tolerable levels for any critical organ (e.g., 3,000
cGy for the liver; 2,000 cGy for the lungs and kidneys).

- Other: Any experimental therapy (i.e., drugs, biologics, procedures) for the primary
malignancy, either during or within four weeks prior to study entry.

Patient Characteristics/

Inclusion Criteria:

- Performance Status: Patients with a Karnofsky performance status > 70% (or
equivalent, ECOG 0-1) and an expected survival rate of at least 3 months

- Hematopoietic: Hemoglobin > 10g/dL; WBC > 3000 per mm3; Granulocyte count > 1500 per
mm3; platelet count > 100,000 per mm3

- Hepatic: Total bilirubin < 1.5 times the institutional upper limit of normal (IULN);
AST or ALT < 2 X IULN

- Renal: Creatinine < IULN

- Cardiovascular: Patients with LVEF >/= 50% by required MUGA/2D-ECHO study

- Pulmonary: Patients with DF and FEV1 >/= 60 % by required Pulmonary Function Tests

- Gastrointestinal:Patients with severe anorexia or other related symptomology are
excluded

- Central Nervous System: Patient with known metastatic disease to the CNS are excluded

- Other: Patients who have had a prior imaging study with a murine antibody may be
included. Patients agreeing to use a medically effective method of contraception
during and for a period of three months after the treatment period. A pregnancy test
will be preformed on each premenopausal female of childbearing potential immediately
prior to entry into the study. Patients able to understand and give written informed
consent.